Pictet Asset Management’s CRISPR Therapeutics CRSP Stock Holding History

Pictet Asset Management’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$6.87M	Sell	154,007 -13,457	-8%	-$710K	0.01%	729
2025 Q4	$9.02M	Sell	167,464 -25,129	-13%	-$1.5M	0.01%	695
2025 Q3	$12.3M	Sell	192,593 -43,327	-18%	-$2.49M	0.01%	626
2025 Q2	$11.2M	Sell	235,920 -10,166	-4%	-$393K	0.01%	628
2025 Q1	$9.07M	Sell	246,086 -26,618	-10%	-$1.13M	0.01%	685
2024 Q4	$10.7M	Buy	272,704 +22,414	+9%	+$1.06M	0.01%	648
2024 Q3	$11.8M	Buy	250,290 +59,882	+31%	+$3.04M	0.01%	609
2024 Q2	$10.3M	Sell	190,408 -130,115	-41%	-$7.53M	0.01%	621
2024 Q1	$22.2M	Buy	320,523 +311,849	+3,595%	+$22.3M	0.02%	475
2023 Q4	$543K	Hold	8,674	–	–	﹤0.01%	1224
2023 Q3	$394K	Buy	+8,674	New	+$448K	﹤0.01%	1339

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GSK plc London $599M AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Pictet Asset Management's CRSP Position: Q1 2026 in Review

Pictet Asset Management reduced its CRISPR Therapeutics (CRSP) stake by 8% in Q1 2026, selling an estimated $710K and leaving 154,007 shares worth $6.87M. The position accounts for 0.01% of the portfolio, ranked #729.

Pictet Asset Management first reported a position in CRSP in Q3 2023 and has held it in 11 quarters since. The position peaked at $22.2M in Q1 2024. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

Pictet Asset Management held 154,007 shares of CRISPR Therapeutics worth $6.87M as of Q1 2026.
Pictet Asset Management sold 13,457 CRISPR Therapeutics shares in Q1 2026, an estimated $710K.
CRISPR Therapeutics made up 0.01% of Pictet Asset Management's portfolio in Q1 2026, its #729 holding.
Pictet Asset Management first reported a position in CRISPR Therapeutics in Q3 2023 and has held it in 11 quarters since.
Pictet Asset Management's CRISPR Therapeutics position peaked at $22.2M in Q1 2024.
488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Pictet Asset Management's 13F filing for Q1 2026, filed 22 Apr 2026.